The increased emergence of antibiotic resistant bacteria is a growing public health concern, and although new drugs are constantly being sought, the pace of development is slow compared to the evolution and spread of multidrug resistant species. In this study, we developed a novel broad-spectrum antimicrobial agent by simply transforming vancomycin into nano-form using sonochemistry. Vancomycin is a glycopeptide antibiotic largely used for the treatment of infections caused by Gram-positive bacteria, but inefficient against Gramnegative species. The nanospherization extended its effect towards the Gram-negative Escherichia coli and Pseudomonas aeruginosa, making these bacteria up to 10 and 100 times, respectively, more sensitive to the antibiotic. The spheres were able to disrupt the outer membranes of these bacteria, overcoming their intrinsic resistance towards glycopeptides. The penetration of nanospheres into a Langmuir monolayer of bacterial membrane phospholipids confirmed the interaction of the nano-antibiotic with the membrane of Escherichia coli cells, affecting their physical integrity as further visualized by scanning electron microscopy. Such mechanism of antibacterial action is unlikely to induce mutations in the evolutionary conserved bacterial membrane therefore reducing the possibility of acquiring resistance. Our results indicated that the nanotransformation of vancomycin could overcome the inherent resistance of Gram-negative bacteria towards this antibiotic, and disrupt mature biofilms at antibacterial-effective concentrations.
Introduction
Bacterial infections caused by antibiotic resistant strains are one of the world's public health challenges, 1 thus the development of novel therapeutic approaches have been extensively researched. Special focus has been given to Gram-negative bacteria, which outer and inner membranes, porins and efflux pumps form a complex barrier system impermeable to many clinically relevant antibiotics. These inherent structural characteristics impart Gram-negative bacteria a first line of defense against bactericides. 2, 3 Vancomycin, a member of a class of several clinically used antibiotics including teicoplanin, dalbavancin, oritavancin, and telavancin, is a glycopeptide that is structurally unrelated to any available antibiotic. It inhibits bacterial cell wall synthesis through a five-hydrogen bond interaction between the heptapeptide backbone of the antibiotic and the C-terminal L-Lys-Dalanyl-D-alanine dipeptide, a component of bacterial peptidoglycan, extending from the cell wall. 4 This peptide is located in the periplasmic space, which is directly accessible to antibiotics in Gram-positive bacteria. By contrast, vancomycin is inefficient against Gramnegative bacteria due to its large molecular size and inability to penetrate the outer bacterial membrane, which makes the bacteria intrinsically resistant to vancomycin.
Nanotechnology has been considered as a novel tool for overcoming microbial resistance development. Liposomes, nanocapsules and particles are commonly investigated as drug carriers for delivering antimicrobial agents to the infection site, enhancing their clinical effectiveness. [5] [6] [7] However, the transformation of the antimicrobial agents themselves into nano-sized entities has been only sparsely reported. 8, 9 The assemblies of the molecules at nanometer dimensions have unique properties, differing from those of the free molecules and the bulk materials with the same composition. 5 Nanotransformations of antimicrobial agents into nanospheres (NSs) have been carried out in our group using the ultrasonic emulsification method. 8, 10, 11 This approach drastically changes the physical properties of the sonochemically 4 processed compounds allowing for novel modes of action towards bacteria. Antibacterials processed into nano-sized particles are claimed to be more efficient than their non-processed counterparts. 5, 6, 8 The exact mechanisms by which nanomaterials interact with bacteria are not fully understood, but it is thought that the nanoparticles cause an increase in the microbial cell membrane permeability, osmotic damage, and flow of cytoplasmic components out of the cell, eventually leading to cell death. 6 This mode of action reduces the possibility of developing new resistant strains, because bacterial membrane is highly evolutionarily conserved and therefore unlikely to be changed by a single gene mutation. 12 In addition, nanoparticulate systems are also able to tackle multiple biological pathways and many concurrent mutations should have to occur in bacteria in order to develop resistance. 5 Besides avoiding the occurrence of antibiotic resistance, nanotechnology has been considered an efficient tool to control biofilm-associated infections. [13] [14] [15] [16] In fact, the biofilm mode of growth is by itself a resistance mechanism that bacteria use to survive in harsh environments.
Bacteria encased in biofilms are over 1000 times more resistant to antibiotics and host immune system than in culture. 17, 18 Infections due to biofilms are very difficult to treat and account for the increased morbidity and mortality in hospitals. 19 This work aims at developing vancomycin NSs with antibacterial efficiency against Gramnegative species. We hypothesized that sonochemical nano-spherization of vancomycin would extend its activity to Gram-negative bacteria, relying on bacterial membrane disturbance effect. We additionally expected to improve the activity of vancomycin towards bacteria embedded in biofilms, due to enhanced penetration of the NSs into the biofilm matrix. The single step nanotransformation process will save on time-and resourceconsuming screening for new drug entities. Since the chemical structure and the target of the drug will not be altered by adding a new mechanism of activity, such structural engineering 5 rather than synthetic approach would shorten the validation process in terms of novel antibiotic development. The fact that only two new classes of antibiotics with limited activity against Gram-negative bacteria have been introduced into the clinic over the last two decades, supports the timeliness of this study.
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Results and discussion
Vancomycin exerts its antimicrobial activity against Gram-positive bacteria binding to a LLys-D-alanyl-D-alanine dipeptide present in the bacterial peptidoglycan layer and inhibiting the cell wall synthesis, which leads to bacterial lysis and death. However, the double membrane of the Gram-negative bacteria is impermeable to the large glycopeptide molecules of vancomycin, restricting their access to the targeted dipeptide and therefore neutralizing their antibacterial efficiency. Examples of vancomycin-insensitive bacteria are the Escherichia coli (E. coli) in urinary tract infections, and the Pseudomonas aeruginosa (P.
aeruginosa) in bloodstream infections and pneumonia. 22 These clinically relevant Gramnegative species together with the Gram-positive S. aureus were first tested for susceptibility to the non-processed vancomycin. The Gram-negative bacteria showed to be insensitive even to high vancomycin concentrations, while S. aureus was fully eradicated at antibiotic dosage above 15 μg/mL (O.D. 600 ≈ 0 in Fig. 1 ). Aiming at extending the activity spectrum of vancomycin also to Gram-negative bacteria, the free drug was sonochemically processed into NSs.
6 Figure 1 . P. aeruginosa, E. coli and S. aureus growth assessed at optical density at 600 nm (O.D. 600 ) after 24 h incubation with vancomycin in solution (0 -62.5 µg/mL).
We previously applied this nano-formulation approach to boost the antibacterial activity of biopolymers such as aminocellulose and thiolated chitosan as well as other antibiotics such as penicillin. 8, 11, 23, 24 Nanoparticle tracking analysis (NTA) of the sonochemically generated control NSs (without antibiotic) and vancomycin NSs revealed average particle sizes of 115 ± 2 nm and 147 ± 5 nm, respectively (Fig. S2) . The nanosized vancomycin spheres were further observed by transmission electron microscopy (TEM) (Fig. 2) . Zeta potential measurements confirmed a stable suspension of negatively charged spheres (-50 ± 0.5 mV), owing to the use of a non-ionic surfactant (poloxamer 407) in the process of spheres generation. This was further evidenced by the long-term physical stability of the vancomycin NSs, which did not aggregate in solution for more than 6 months stored at 4 ºC. In order to assess the amount of the encapsulated vancomycin, the NSs were separated from the bulk solution by ultracentrifugation, and both supernatant and NSs were analyzed by HPLC (Fig. S1) . The difference between the antibiotic concentration in the supernatant and the solution prior to the sonication revealed that only 15 % of vancomycin was transformed into NSs (Table S1 ). However, the amount of vancomycin quantified after NSs demulsification (disassembling with ethanol) was 2-fold lower (7.5 ± 0.8 %) probably because of the affinity partitioning of the antibiotic into the hydrophobic vegetable oil phase of the biphasic system. 25 Most likely, part of vancomycin was retained in the NS shell readily acting on bacteria, while the remaining antibiotic formed the sphere core, being inaccessible to bacteria at first, but gradually released over time.
We further investigated whether the conversion of vancomycin into NSs was accompanied by any structural or chemical changes. FTIR spectra were acquired for both vancomycin and vancomycin NSs, as well as for the oil and surfactant used to form the NSs (Fig. 3) . The 8 spectra did not revealed any changes in the chemical structure of vancomycin upon spherization. The new peak appearing at 1750 cm -1 corresponds to the presence of oil (inset in Fig. 3 ), whereas the increase of the broad band at 3500 cm -1 was assigned to hydrogen bonding effect due to the stretching of the hydroxyl groups in vancomycin. Therefore, we may conclude that the sonochemically-induced formation of vancomycin NSs led to the creation of a hydrogen bond network contributing to the stabilization of the spheres. Similar effect has been observed processing sonochemically penicillin NSs and tetracycline nanoparticles. Cationic nanoparticles are reported to interact with negatively charged microbial membranes through electrostatic interactions causing membrane disruption and cell leakage, an effect that 9 we have observed for other positively charged NSs, 8 while negatively charged particles penetrate the cells through nonspecific binding and clustering on the cationic sites of the membrane followed by internalization via endocytosis. 26 The interaction of our negatively charged spheres with a membrane model built with phosphatidylethanolamine (PE), a major constituent phospholipid from E. coli, 27 was studied by Langmuir monolayer technique. The
Langmuir technique is widely used for building monolayers mimicking natural membranes and provides information about the interactions between structural lipids and different molecules or nanoparticulate systems, without considering other constituents of the cell membrane.
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The isotherms of PE using as a subphase water or vancomycin solution presented a lift-off area at ca. 100 Å 2 /molecule, whereas the presence of NSs (both control and vancomycin NSs)
increased this molecular area to around 110 Å 2 /molecule for the control NSs and 165 Å 2 /molecule for the vancomycin NSs. This behavior indicates that PE forms stable monolayers, and the presence of vancomycin in solution does not induce any disturbing effect on the bacterial mimetic membrane. By contrast, the NSs in the subphase significantly expanded the PE monolayers, indicating their strong membrane disturbing effect, especially when vancomycin was included in the NSs (Fig. 4 a) .
After compression, at surface pressure higher than ca. 45 mN/m, the PE isotherms with control and vancomycin NSs in the subphase nearly overlap with the isotherm with only water in the subphase. Although the slope of these isotherms was still different, this behavior
indicates that, at high surface pressures, part of the NSs are expelled from the monolayer down to the solution. 29 However, at the characteristic surface pressure of natural bacterial cell membranes (33 mN/m), 30 the PE monolayer with a subphase containing vancomycin NSs was still expanded when compared to the PE isotherm with vancomycin in solution, control NSs and water in the subphase (Fig. 4 a) , suggesting that these NSs induce a strong disturbing effect on the membrane that may result from their protruding in between the phopholipid molecules at the air-water interface. 8, 11 To corroborate these results, control NSs, vancomycin NSs and vancomycin in solution were injected into the subphase beneath the PE monolayer, previously formed at 33 mN/m, and the increase on the surface pressure was recorded with time ( Fig. 4 c) . The increase of the surface pressure as a function of time demonstrated the membrane disrupting effect of both vancomycin NSs and control NSs while no effect was observed when the subphase contained vancomycin in solution. The vancomycin NSs, however, induced a higher surface pressure increase when compared to the control NSs, accounting for their membrane disturbing effect.
Analyzing the compressibility modulus (C s −1 ) calculated from the slope of the π-A isotherm in Therefore, this indicated that NSs avoided the packing of the phospholipid molecules in the membrane, reducing the C s −1 maximum value and avoiding the formation of highly compact states, thereby conferring fluidity to the membrane (Fig. 4 b) . 29 These results confirmed one more time the capacity of vancomycin NSs to disturb the bacterial membrane model. In order to validate the disturbing effect of the vancomycin NSs on the PE membrane model, the Langmuir-Blodgett (LB) films were transferred to mica and the interaction between the NSs and the membrane model was verified using atomic force microscopy (AFM) (Fig. 5 a) .
AFM maps the profile/height of the monolayer surface, which is altered by the presence of NSs underneath. The light and dark shades in the AFM images correspond to different heights of the monolayer surface. At low surface pressures, the PE with water in the subphase formed a uniform and compact monolayer with no relevant structures observed (Fig. 5 a, left image),
while PE with vancomycin NSs in the subphase produced bright round patches (Fig. 5 a, right image), which indicates that the integrity of the membrane was affected by the spheres. The round patches mean that the PE monolayer is in a LC state, whereas the rest of the lipid molecules are in a more fluid (LE) state, corresponding to the dark shade in the AFM image.
Thus, the surface profile of the PE monolayer confirmed its disturbance by the vancomycin NSs. To further corroborate the membrane disturbing effect of the NSs demonstrated in Fig. 4 and 5a the vancomycin NSs were incubated with E. coli and the changes in cell morphology were visualized using scanning electron microscopy (SEM) (Fig 5 b) . The non-treated E. coli cells were intact with a typical rod like shape, smooth surface and size about 0. Proven the fact that the NSs of vancomycin were able to disturb the biomimetic membrane and alter the morphology of bacterial cells, we further analyzed the antimicrobial and antibiofilm activities of the NSs towards two Gram-negative species. The vancomycin NSs induced a 2.8 log reduction of P. aeruginosa (**P ≤ 0.01) and 1.9 log reduction of E. coli (*P < 0.05) growth, while vancomycin in solution (using the same dilution factor) caused less than 0.8 log reduction of both microorganisms (Fig. 6) . A 4-and 3-fold improvement, respectively, was attained in the inhibition of these planktonic Gram-negative bacteria. It is worth mentioning that the nanotransformation of vancomycin plays a key role in the inhibition of bacterial growth, considering the low concentration of antibiotic in the spheres.
14 concentration at the site of bacteria. Such effect has been reported when a combination of nanoparticles and antibiotics was applied. 26 Recent studies have also shown that combining nanoparticles with antibiotics not only reduced the toxicity of both agents towards human cells by decreasing the requirement for high dosages, but also enhanced their bactericidal
properties. The nanoparticle ability to destroy antibiotic-resistant bacteria has also been shown. 26 In our study, the enhanced killing effect was due to the nanotransformation of the antibiotic itself, instead of its encapsulation, thereby combining both bactericidal and nanoscale effects in a single construct. Therefore, we believe that nonspecific binding and diffusion as well as membrane damage, govern the antibacterial efficiency of the vancomycin NSs against Gram-negative bacteria.
In a next step, we evaluated the effect of the nanoformulated vancomycin on biofilms of
Gram-negative bacteria. Vancomycin either in solution (125 μg/mL) or in the form of NSs (≈ 1.05 ± 0.06 x 10 13 NSs/mL) was applied on mature biofilms and the effect on the cells viability was assessed by fluorescence microscopy after Live/Dead staining (Fig. 7) . The biofilm disruption was more pronounced upon treatment with the antibiotic NSs, and in the case of P. aeruginosa, a large number of red stained cells, i.e. dead bacteria, was observed.
The control NSs without antibiotic neither decreased the biomass nor killed the E. coli confirming that the nanoparticulate form alone is not able to eradicate the biofilm form of the bacterium. On the other hand, the red stained cells detected in the P. aeruginosa biofilm, treated with control and vancomycin NSs, may result either from antibacterial effect due to membrane disturbance, or from staining of the extracellular DNA component of P.
aeruginosa biofilm by the propidium iodide dye used for cells viability assessment. vancomycin NSs significantly decreased P. aeruginosa (**P < 0.01) and E. coli (*P < 0.05) cells within the biofilm when compared to vancomycin in its bulk form. P. aeruginosa was at least 10 times (ca. 1 log reduction) more susceptible to the antibiotic NSs than E. coli (Fig. 8) .
In contrast, we did not observe any decrease of the live bacterial cells in the biofilm upon the application of vancomycin solution, corroborating the results found by fluorescence microscopy and antibacterial assays ( Fig. 6 and 7) .
Expectedly, the activity of vancomycin NSs on the sessile bacteria was lower than on the planktonic cells because of the increased resistance provided by the build-up of the biofilm matrix. Besides the conventional resistance mechanisms, the biofilm-grown bacterial cells express properties distinct from the planktonic cells that play important role in their resistance to the most common antimicrobials. 18 Our NSs do not possess hydrolytic activity to degrade the biofilm matrix components, e.g. extracellular polysaccharides, but they were able to eradicate P. aeruginosa and E. coli cells in the mature biofilms. This effect could be attributed to the nano-form of the antibiotic and its enhanced penetration through the biofilm to reach the bacteria embedded therein. The interaction between the biofilms and NSs is a complex interplay of particles characteristics, such as charge and size, and biofilm features. It is possible that the negatively charged vancomycin NSs interact electrostatically with oppositely charged matrix molecules and attach to the biofilm structure. 33 Once NSs are adsorbed on the biofilm they may diffuse deeper into it or accumulate within the matrix as a consequence of the active outgrowth of the biofilm, forming new layers above the NSs.
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The obtained antibiotic NSs could be further used in either free form or engineered as coatings for controlling bacterial infections and the emergence of drug resistance. They could be exploited in a wide range of biomedical applications, such as antibacterial and anti-biofilm indwelling medical devices and implants, hospital textiles, skin care products for treatment of skin infections, and wound dressings. 
Materials and methods
Materials
The bacterial strains: Staphylococcus aureus (S. aureus ATCC 25923), Escherichia coli (E. 
Sonochemical preparation of vancomycin nanospheres
Vancomycin NSs were prepared by an adaptation of the Suslick method. 34 Briefly, a two- kHz Ti horn at 35% amplitude. The bottom of the probe was positioned at the aqueousorganic interface, employing an acoustic power of ~ 0.5 W/cm 3 for 3 min using an ice-cooling bath. The resulted NSs dispersion was purified by three consecutive centrifugations at 1500 rpm for 15 min, for the removal of the organic phase, followed by an ultracentrifugation at 14 000 rpm for 45 min and re-suspension in water for separation of the NSs from the solution.
Nanospheres characterization
NTA was used to determine the size of the NSs and their number per mL. NTA was performed in flow mode with a NanoSight LM10 instrument (Malvern Instruments Inc., UK)
equipped with LM10 Laser 405 nm nanoparticle viewing unit and sCMOS camera. NTA Software NTA 3.0 was used to capture several frames of the NSs suspension and correlate the analyzed using essential eFTIR-3.00.019 software.
Vancomycin concentration in the nanospheres
The amount of vancomycin transformed into NSs was determined by high-performance liquid chromatography (HPLC) as previously described. 35 The analysis was performed using an Agilent Technologies 1200 HPLC system, consisting of a degasser, a quaternary pump, and an automatic sample injector. The system also includes a diode array detector for recording the absorption spectra of the samples. A Microsorb-MV C-18 reserved-phase column (150 x 4.6 mm, 5 µm particle size) was used to perform the chromatographic separation. The flow rate was 1 mL/min and the vancomycin was detected at 214 nm. Gradient elution was carried Live/dead kit: P. aeruginosa and E. coli biofilms were grown on tissue culture-treated polystyrene 24-well plates for 24 h at 37 °C as previously described. 37, 38 Then, the biofilm was washed with tryptic soy broth (TSB) under aseptic conditions to eliminate non-adhered bacteria and 1 mL of the samples diluted 2 times in TSB to obtain a concentration of 125 μ g/mL of vancomycin and 2.1 ± 0.1 x 10 13 NSs/mL of vancomycin NSs and control NSs, was added to each well. After exposure to vancomycin solution, and vancomycin NSs and control
NSs for 24 h at 37 °C the solutions were discarded and biofilm washed with 0.9 % sodium chloride (NaCl) pH 6.5. The biofilm disruption was analyzed using Live/Dead BacLight kit according to the instructions of the manufacturer. The Live/Dead kit contains two nucleic acid stains -green-fluorescent Syto 9 that labels all viable bacteria in the population in green and red-fluorescent propidium iodide that labels dead bacteria in red. After washing with 1 mL 0.9 % NaCl pH 6.5 the biofilms were stained for 15 min in the dark with a mixture of both stains
(1 : 1) and observed using fluorescence microscopy at 480/500 nm for Syto 9 and at 490/635 nm for propidium iodide. Biofilms non-treated with antibiotic were used as a negative control (lack of biofilm eradication). NSs/mL, respectively, and their interaction with E. coli PE monolayers was evaluated. The
Calgary Biofilm
Langmuir trough was cleaned with chloroform and water several times. Afterwards, the subphase (MilliQ water containing vancomycin, control or vancomycin NSs) was poured into the through and 35 µL of 0.5 mg/mL PE solution in chloroform were spread dropwise with a gas-tight syringe. The isotherm recording was performed after the complete spreading and 26 evaporation of the chloroform (10 minutes). All the experiments were carried out at least three times with barrier closing rates at 25 cm 2 /min.
The interaction of the vancomycin NSs with the PE monolayers was also studied by AFM.
The LB film transfer was conducted dipping the freshly cleaved mica through the air liquid interface on the subphase before adding the solution, waiting five minutes for monolayer stabilization after pressure set point (5 mN/m) was achieved, obtaining transfer ratios > 80 %.
AFM topographic images of LB films were acquired in an air tapping mode using a
Multimode AFM controlled by Nanoscope IV electronics (Veeco, Santa Barbara, CA) under ambient conditions. Triangular AFM probes with silicon nitride cantilevers and silicon tips were used (SNL-10, Bruker) (nominal spring constant of 0.35 N/m and a resonant frequency of 50 kHz). Images were acquired at 1.5 Hz line frequency and at minimum vertical force to reduce sample damage.
NSs insertion into phospholipid monolayer:
The kinetics of insertion of vancomycin NSs and control NSs into monolayers was measured using the E. coli PE monolayer built at π = 33 mN/m, corresponding to the pressure of natural cell membranes. 30 Briefly, 35 µL of 0.5 mg/mL of PE was spread in MilliQ water and the monolayer was compressed to 33 mN/m.
After the PE monolayer stabilization, 300 µL of the vancomycin solution and NSs to a final concentration of 2.5 µg/mL and 2.1 ± 0.13 x 10 8 NSs/mL, respectively were injected in the subphase. The changes in the π were monitored over the time.
Data analysis
Replicate samples were used for each measurement, and all the values are presented as mean values ± the respective standard deviations (SD). Results were analysed using graph pad prism version 7.0c (Graph Pad Software, San Diego, CA, U.S.A.). Statistical significances were determined using a one-way ANOVA followed by the Dunnett post-hoc test or by the
